Covid-19: The intranasal Covid vaccine iNCOVACC from Bharat Biotech will go on sale in the fourth week of January for Rs 325 in public hospitals and Rs 800 in private hospitals. The vaccine has been authorised to be distributed as a booster dosage for people above the age of 18 and will be listed on the CoWin app.
CDSCO) gives nod to Bharat Biotech to employ heterologous booster dosages of iNCOVACC
The Central Drugs Standard Control Organization (CDSCO) gave Bharat Biotech permission to employ heterologous booster dosages of iNCOVACC earlier this month. Following booster dose tests with 875 participants at 9 trial sites across India, the national drug regulatory agency granted its approval.
A heterologous booster is when a person receives a third dose of a different vaccination from the one that was given as the initial dose.
Mucosal IgA antibody levels were significantly elevated in the iNCOVACC recipients (measured in the saliva). According to the press release, mucosal IgA antibodies in the upper respiratory tract may help prevent infections and transmission.
Also Read: Naegleria fowleri: “Brain-eating amoeba” claims first life in South Korea
Executive chairman of Bharat Biotech informs
“We have developed COVAXIN and iNCOVACC, two Covid vaccines from two different platforms, with two different delivery systems. The vector intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunisation during public health emergencies and pandemics,” said Dr. Krishna Ella, executive chairman of Bharat Biotech.
In comparison to injections, nasal vaccinations offer a number of advantages. In addition to blocking the virus’ entry routes, nasal vaccines are simple to store, produce little waste, and are simple to administer.
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER
